CLAIMS

1. A parapoxvirus agent for use in (i) conditioning a subject for a coronavirus infection or (ii) treating a coronavirus infection in a subject.

2. The parapoxvirus agent for use according to claim 1, wherein the parapoxvirus is *Parapoxvirus ovis* (PPVO).

3. The parapoxvirus agent for use according to claim 1 or 2, wherein the parapoxvirus agent is:
(a) the parapoxvirus itself or a fragment thereof, or
(b) an agent that comprises genetic information encoding for (a),
preferably wherein the parapoxvirus agent is an inactivated PPVO virion.

4. The parapoxvirus agent for use according to any one of claims 1 to 3, wherein the coronavirus is a SARS coronavirus.

5. The parapoxvirus agent for use according to any one of claims 1 to 4, wherein the coronavirus is SARS-CoV-2 or a variant thereof with at least 80% sequence identity to SEQ ID NO: 1 or 2.

6. The parapoxvirus agent for use according to any one of claims 1 to 5, wherein the subject to be conditioned is characterized by one or more risk factors for contracting a coronavirus infection and/or by one or more risk factors for having a severe course of coronavirus disease.

7. The parapoxvirus agent for use according to any one of claims 1 to 5, wherein the subject to be treated is asymptomatic.

8. The parapoxvirus agent for use according to any one of claims 1 to 5, wherein the subject to be treated has coronavirus disease, preferably Covid-19.

9. The parapoxvirus agent for use according claim 8, wherein the subject has either no severe symptoms, or has a severe course of coronavirus disease.

10. The parapoxvirus agent for use according to any one of claims 1 to 9, wherein the use comprises the administration of a further treatment regimen for (i) or (ii).

11. The parapoxvirus agent for use according claim 10, wherein the further treatment regimen for (i) comprises administering a coronavirus agent and/or an immune stimulatory agent, and the further treatment regimen for (ii) comprises administering a coronavirus agent, one or more further medicaments and/or one or more further non-drug treatments.

12. The parapoxvirus agent for use according claim 11, wherein

- the coronavirus agent is selected from the group consisting of:
  (a) the coronavirus itself or a fragment thereof,
  (b) an agent that comprises genetic information encoding for (a), and
  (c) an agent which is capable upon administration of an effective amount thereof to a subject infected with coronavirus to interfere with the infection of a cell by the coronavirus or with the replication of the coronavirus within a cell;
- the further medicament is selected from the group consisting of an immune stimulatory agent, an antiviral, an antibiotic, an adjuvant, a glucocorticoid, an antihypertensive drug, an hypoglycaemic drug, an anti-shock drug, and a drug suitable for treating one or more symptoms of coronavirus disease; and/or
- the one or more further therapies are preferably selected from the group consisting of oxygen therapy and extra-corporeal organ support (ECOS).

13. The parapoxvirus agent for use according to any one of claims 1 to 12, wherein the parapoxvirus is capable upon administration of an effective amount thereof to a subject infected with coronavirus to
(i) increase the number of one or more of coronavirus-antigen-specific immune factors,
(ii) inhibit coronavirus replication,
(iii) reduce the coronavirus load, and/or
(iv) prevent or ameliorate a coronavirus-specific cytokine profile or a cytokine storm.

14. A composition or a kit comprising a parapoxvirus agent, preferably as defined in claim 3, and a coronavirus agent, preferably as defined in claim 12.

15. A pharmaceutical composition or kit for use in (i) conditioning a subject for a coronavirus infection or (ii) treating a coronavirus infection in a subject, wherein the pharmaceutical composition or kit comprises a parapoxvirus agent, preferably as defined in claim 3, and preferably a further medicament, more preferably as defined in claim 12.